KR20050044582A - 위식도 역류 질환의 치료를 위한 신규한 용도 - Google Patents

위식도 역류 질환의 치료를 위한 신규한 용도 Download PDF

Info

Publication number
KR20050044582A
KR20050044582A KR1020047007819A KR20047007819A KR20050044582A KR 20050044582 A KR20050044582 A KR 20050044582A KR 1020047007819 A KR1020047007819 A KR 1020047007819A KR 20047007819 A KR20047007819 A KR 20047007819A KR 20050044582 A KR20050044582 A KR 20050044582A
Authority
KR
South Korea
Prior art keywords
cannabinoid receptor
receptor agonist
acceptable salt
pharmaceutically acceptable
reflux
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020047007819A
Other languages
English (en)
Korean (ko)
Inventor
안데르스 레만
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20050044582A publication Critical patent/KR20050044582A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020047007819A 2001-11-23 2002-11-20 위식도 역류 질환의 치료를 위한 신규한 용도 Withdrawn KR20050044582A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936-1 2001-11-23
SE0103936 2001-11-23

Publications (1)

Publication Number Publication Date
KR20050044582A true KR20050044582A (ko) 2005-05-12

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047007819A Withdrawn KR20050044582A (ko) 2001-11-23 2002-11-20 위식도 역류 질환의 치료를 위한 신규한 용도

Country Status (20)

Country Link
US (1) US7358245B2 (https=)
EP (1) EP1453497A1 (https=)
JP (1) JP2005511632A (https=)
KR (1) KR20050044582A (https=)
CN (1) CN1610542A (https=)
AR (1) AR037299A1 (https=)
AU (1) AU2002353700A1 (https=)
BR (1) BR0214319A (https=)
CA (1) CA2466916A1 (https=)
HU (1) HUP0402080A3 (https=)
IL (1) IL161748A0 (https=)
IS (1) IS7272A (https=)
MX (1) MXPA04004774A (https=)
NO (1) NO20042613L (https=)
NZ (1) NZ532844A (https=)
PL (1) PL369402A1 (https=)
RU (1) RU2280443C2 (https=)
TW (1) TW200407110A (https=)
WO (1) WO2003043619A1 (https=)
ZA (1) ZA200403785B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039550A2 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
US8628796B2 (en) * 2004-12-09 2014-01-14 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
CA2698752A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
EP2205240A1 (en) * 2007-10-02 2010-07-14 Ariel-University Research And Development Company, Ltd. Endocannabinoids for enhancing growth and development in infants
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
EP0887340A4 (en) * 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
AU6690001A (en) * 2000-06-15 2001-12-24 Schering Corp Thrombin receptor antagonists
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Also Published As

Publication number Publication date
JP2005511632A (ja) 2005-04-28
CN1610542A (zh) 2005-04-27
CA2466916A1 (en) 2003-05-30
HUP0402080A3 (en) 2008-03-28
BR0214319A (pt) 2004-11-03
IS7272A (is) 2004-05-19
US20040266861A1 (en) 2004-12-30
RU2280443C2 (ru) 2006-07-27
WO2003043619A1 (en) 2003-05-30
EP1453497A1 (en) 2004-09-08
HUP0402080A2 (hu) 2005-02-28
PL369402A1 (en) 2005-04-18
WO2003043619A8 (en) 2005-03-17
AR037299A1 (es) 2004-11-03
RU2004114843A (ru) 2005-05-27
US7358245B2 (en) 2008-04-15
NZ532844A (en) 2005-12-23
IL161748A0 (en) 2005-11-20
TW200407110A (en) 2004-05-16
ZA200403785B (en) 2005-05-19
AU2002353700A1 (en) 2003-06-10
MXPA04004774A (es) 2004-07-30
NO20042613L (no) 2004-08-13

Similar Documents

Publication Publication Date Title
KR100770695B1 (ko) 말초 카나비노이드 수용체 특이적 아고니스트
EP1807083B1 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
EP1604665B1 (en) C-kit kinase inhibitor
TW202135796A (zh) 口服大麻素調配物
KR100902799B1 (ko) 키마제 저해제 및 ａｃｅ 저해제를 유효성분으로 함유하는약제
RU2324484C2 (ru) Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
EP3458448B1 (en) Fasn inhibitors for use in treating non-alcoholic steatohepatitis
CH678919A5 (https=)
KR20050044582A (ko) 위식도 역류 질환의 치료를 위한 신규한 용도
CN113784709B (zh) 用于治疗炎症性病症的化合物和方法
JP2003238417A (ja) フロレチン配糖体の安定化組成物、該安定化組成物を含有する糖尿病予防・治療剤、および保健食品
KR20250152044A (ko) 멜리사엽 분획 추출물 및 이를 포함하는 신규 약학적 조성물
JP2015507006A (ja) ユリノキの樹皮のエキスを有効成分として含有する改善された医薬製剤
KR101085970B1 (ko) 쿠마린 유도체를 유효성분으로 함유하는 위장 질환 예방 또는 치료용 조성물
EP4134091B1 (en) Fraction extract of melissa officinalis leaves and novel pharmaceutical composition including same
CN119095592A (zh) 大麻素的不良心血管作用的治疗
WO2005123053A2 (en) Use of cb2 receptors agonists for the treatment of huntington’s disease
KR20240128504A (ko) 산 펌프 억제 활성을 갖는 신규 벤즈이미다졸 유도체
KR20240055482A (ko) 글리코겐 가인산분해효소 (pygl) 저해제를 유효성분으로 포함하는 염증성 장 질환 치료용 약학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040521

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid